Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing
Codexis (NASDAQ: CDXS) and Nitto Denko Avecia announced an evaluation agreement dated Oct. 29, 2025 for Codexis' ECO Synthesis® Manufacturing Platform. Under the agreement, Nitto Denko Avecia will evaluate the enzyme‑catalyzed ECO Synthesis approach that replaces traditional solid‑phase oligonucleotide synthesis.
The collaboration is intended to enable future licensing discussions and broader adoption of the platform, and to explore scalable, sustainable manufacturing for therapeutic siRNA by combining Codexis' enzymatic technology with Nitto Denko Avecia's CDMO expertise.
Codexis (NASDAQ: CDXS) e Nitto Denko Avecia hanno annunciato un accordo di valutazione datato 29 ottobre 2025 per la ECO Synthesis® Manufacturing Platform di Codexis. In base all'accordo, Nitto Denko Avecia valuterà l'approccio ECO Synthesis catalizzato da enzimi che sostituisce la tradizionale sintesi solida di oligonucleotidi.
La collaborazione è finalizzata a facilitare future discussioni su licenze e una più ampia adozione della piattaforma, nonché a esplorare una produzione scalabile e sostenibile per lo lo siRNA terapeutico combinando la tecnologia enzimatica di Codexis con l'esperienza CDMO di Nitto Denko Avecia.
Codexis (NASDAQ: CDXS) y Nitto Denko Avecia anunciaron un acuerdo de evaluación fechado el 29 de octubre de 2025 para la plataforma de fabricación ECO Synthesis® de Codexis. En virtud del acuerdo, Nitto Denko Avecia evaluará el enfoque ECO Synthesis catalizado por enzimas que reemplaza la síntesis oligonucleotídica en fase sólida tradicional.
La colaboración tiene como objetivo facilitar futuras discusiones de licencias y una adopción más amplia de la plataforma, así como explorar una fabricación escalable y sostenible para siRNA terapéutico al combinar la tecnología enzimática de Codexis con la experiencia CDMO de Nitto Denko Avecia.
Codexis (NASDAQ: CDXS)와 Nitto Denko Avecia는 Codexis의 ECO Synthesis® Manufacturing Platform에 대해 2025년 10월 29일자로 평가 계약을 발표했습니다. 이 계약에 따라 Nitto Denko Avecia는 전통적인 고체상 올리고뉴클레오타이드 합성을 대체하는 효소 촉매 ECO Synthesis 접근법을 평가합니다.
이번 협력은 향후 라이선스 협의의 가능성과 플랫폼의 더 넓은 도입을 가능하게 하고, Codexis의 효소 기술과 Nitto Denko Avecia의 CDMO 전문성을 결합하여 치료용 siRNA에 대한 확장 가능하고 지속 가능한 제조를 모색하는 것을 목표로 합니다.
Codexis (NASDAQ: CDXS) et Nitto Denko Avecia ont annoncé un accord d'évaluation daté du 29 octobre 2025 pour la plateforme de fabrication ECO Synthesis® de Codexis. Dans le cadre de l'accord, Nitto Denko Avecia évaluera l'approche ECO Synthesis catalysée par enzymes qui remplace la synthèse oligonucléotidique en phase solide traditionnelle.
Cette collaboration vise à permettre de futures discussions de licences et une adoption plus large de la plateforme, ainsi qu'à explorer une fabrication évolutive et durable pour le siRNA thérapeutique, en combinant la technologie enzymatique de Codexis avec l'expertise CDMO de Nitto Denko Avecia.
Codexis (NASDAQ: CDXS) und Nitto Denko Avecia gaben eine Evaluierungsvereinbarung mit dem Datum 29. Oktober 2025 für Codexis' ECO Synthesis® Manufacturing Platform bekannt. Im Rahmen der Vereinbarung wird Nitto Denko Avecia den enzymkatalysierten ECO Synthesis-Ansatz bewerten, der die herkömmliche Festphasen-Oligonukleotid-Synthese ersetzt.
Die Zusammenarbeit soll künftige Lizenzverhandlungen und eine breitere Einführung der Plattform ermöglichen und eine skalierbare, nachhaltige Herstellung für therapeutisches siRNA erforschen, indem Codexis' enzymatische Technologie mit der CDMO-Expertise von Nitto Denko Avecia kombiniert wird.
Codexis (NASDAQ: CDXS) و Nitto Denko Avecia أعلنا عن اتفاق تقييم مؤرخ 29 أكتوبر 2025 لـمنصة ECO Synthesis® Manufacturing Platform الخاصة بـ Codexis. بموجب الاتفاق، ستقيّم Nitto Denko Avecia النهج المحفَّز بالإنزيمات ECO Synthesis الذي يحل محل التخليق الإنزيمي التقليدي لل oligonucleotide في الحالة الصلبة.
يهدف التعاون إلى تمكين مناقشات الترخيص المستقبلية واعتماد أوسع للمنصة، واستكشاف تصنيعاً قابلاً للتوسع ومستداماً لـ siRNA العلاجي من خلال الجمع بين التكنولوجيا الإنزيمية لـ Codexis وخبرة CDMO لدى Nitto Denko Avecia.
Codexis (NASDAQ: CDXS) 与 Nitto Denko Avecia 宣布了一份评估协议，日期为 2025年10月29日，适用于 Codexis 的 ECO Synthesis® Manufacturing Platform。根据协议，Nitto Denko Avecia 将评估由酶催化的 ECO Synthesis 方法，该方法取代传统的固相寡核苷酸合成。
此次合作旨在促进未来的授权谈判和更广泛的平台采用，并通过将 Codexis 的酶技术与 Nitto Denko Avecia 的 CDMO 专业知识相结合，探索用于治疗性 siRNA 的可扩展、可持续制造。
- None.
- None.
Insights
Codexis and Nitto Denko Avecia began an evaluation agreement to assess enzyme-based siRNA manufacturing, signalling potential CDMO licensing and scale-up collaboration.
The collaboration pairs Codexis’s ECO Synthesis® Manufacturing Platform, which replaces traditional solid-phase oligonucleotide synthesis with an enzyme-catalyzed approach, with Nitto Denko Avecia’s CDMO manufacturing expertise. The agreement is explicitly an evaluation to test technical fit and manufacturability and may lead to licensing and broader adoption if results support scale-up.
Key dependencies and risks include successful technical validation at the CDMO scale and alignment on licensing terms; neither technical results nor commercial terms are disclosed. Monitor technical evaluation outcomes and any subsequent licensing announcements; expect initial readouts or decisions within typical CDMO evaluation cycles over the next 6–18 months from
Under the terms of the agreement, Nitto Denko Avecia will evaluate Codexis' ECO Synthesis® Manufacturing Platform. The collaboration will pave the way for licensing discussions and broader adoption of the ECO Synthesis platform, which replaces traditional solid-phase oligonucleotide synthesis with a flexible, enzyme-catalyzed approach built to scale.
"We are excited to partner with Nitto Denko Avecia, a recognized leader in therapeutic oligonucleotide manufacturing," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "This collaboration represents a significant milestone toward expanding the reach of our ECO Synthesis® Manufacturing Platform, through best-in-class CDMO collaborations."
"At Nitto Denko Avecia, we are constantly looking to the future of oligonucleotide manufacturing," said Tammy Cooper, President at Nitto Denko Avecia. "Exploring Codexis' ECO Synthesis® Manufacturing Platform reflects our commitment to pioneering next-generation technologies that can redefine scalability, sustainability, and innovation in therapeutic development. This collaboration aligns with our mission to deliver high-quality therapeutics to our partners and patients worldwide."
By combining Codexis' innovative ECO Synthesis® Manufacturing Platform with Nitto Denko Avecia's expertise in manufacturing oligonucleotide therapeutics at scale, this collaboration marks a pivotal step toward advancing scalable and sustainable therapeutic siRNA manufacturing.
About Codexis, Inc.
Codexis is redefining what is possible in therapeutic development and manufacturing, leading the enzymatic technology revolution with efficient, high-quality, and commercially proven solutions. The company's manufacturing platforms consistently outperform legacy methods, enabling the development of therapeutic possibilities that were previously out of reach. With a proven track record, proprietary technology, and unrivalled scientific expertise, Codexis advances technology beyond conventional boundaries. More than a solutions provider, Codexis serves as a trusted long-term partner, committed to driving progress across the healthcare ecosystem. www.codexis.com
About Nitto Denko Avecia, Inc.
Nitto Denko Avecia Inc., is a recognized leader in development and manufacturing services of oligonucleotide therapeutics with facilities in Milford, MA, and Cincinnati, OH that cover preclinical to commercial needs. The company has manufactured more than 1,500 oligonucleotide sequences and developed an extensive late phase portfolio that offers a comprehensive oligonucleotide solution. www.Avecia.com.
About Nitto Denko Corporation
Nitto is a high-performance materials manufacturer. Since its founding in 1918, it has been providing a wide range of products and services globally. These include optical materials such as polarizing films used in display devices, circuit boards, industrial tapes, and medical-related products, all developed based on its eight core technologies. Guided by the brand slogan 'Innovation for Customers,' Nitto strives to create essential values for the world and contribute to a sustainable global environment and a prosperous human society. https://www.nitto.com/jp/en/
View original content:SOURCE Codexis
FAQ
What did Codexis (CDXS) announce on October 29, 2025?
What is the purpose of the evaluation agreement between Codexis and Nitto Denko Avecia?
How does ECO Synthesis® differ from traditional oligonucleotide synthesis?
Will the Codexis and Nitto Denko Avecia agreement lead to a licensing deal?
What part of therapeutics does the Codexis ECO Synthesis evaluation target?
How might this collaboration affect Codexis (CDXS) commercial adoption?
